Backed by ARCHIMED, the deal strengthens connected cardiac diagnostics with integrated Holter, ABPM, and telemedicine solutions
Our company remains focused on advancing monoclonal antibody therapeutics for solid tumors, with a clear emphasis on combination immunotherapy strategies
Collaboration to accelerate mRNA neoantigen therapy development for colorectal and pancreatic cancers using advanced immunology and dark genome insights
The combined offering is designed to support a wide range of applications, from pilot-scale research to high-volume clinical use
The initiative is designed to benefit patients as well as healthcare providers by streamlining access to consultations, diagnostics, and essential care services
SRM Medical College Hospital and Research Centre hosts undergraduate research expo highlighting innovation, interdisciplinary collaboration, and the role of artificial intelligence
With big pharma leaning on external pipelines, the company sees opportunity in de-risked, high-impact assets with clear clinical endpoints
On the generics and biosimilars front, the combined business is expected to benefit from Sun’s portfolio of more than 550 approved ANDAs across multiple dosage forms
Q2 2026 analysis shows expanding approvals, stronger uptake, and a shift toward evidence-driven biosimilar evaluation
The company reported consolidated total income of Rs. 161.3 crore in Q4 FY26, a strong jump from Rs. 120.3 crore in the same period last year
Subscribe To Our Newsletter & Stay Updated
